mouse anti human ip 10  (Bio-Rad)

Journal: medRxiv

Article Title: Characterization of CXCL10 as a biomarker of respiratory tract infections detectable by open-source lateral flow immunoassay

doi: 10.1101/2024.01.12.24301261

Figure Lengend Snippet: A: Schematic of workflow. Pre-processed transcriptomic datasets using the Harmonizome resource (Rouillard et al ., 2006) database of processed microarray datasets under the category “GEO Signatures of Differentially Expressed Genes for Viral Infections” (Edgar et al ., 2002; Barrett et al ., 2013) was accessed for hypothesis testing for elevations in CXCL10 , CXCL11 , and TNFSF10 following viral exposure in vitro from a variety of experimental conditions. This dataset contained 366 individual datasets of mRNA expression profiles using microarray technology. All non-human experiments and non-respiratory viruses were excluded which filtered down to 199 microarray datasets. The studies in which CXCL10, CXCL11 and TNFSF10 appeared to be differentially expressed were counted (*Found in the top 300 or bottom 300 differentially expressed genes with a Harmonizome standard value greater than 1 (up-regulated) or below -1 (down-regulated).) Datasets included but not limited to Calu-3 cell lines, HAE cultures infected with respiratory viruses including but not limited to FluA, SARS-CoV and Human metapneumovirus. B: CXCL10 was found to be upregulated in 39 independent viral infection datasets, and downregulated in one. CXCL11 was upregulated in 33 viral infection datasets. TNFSF10 was upregulated in 36 and downregulated in 3. C: The housekeeping genes GAPDH , TUBB and ACTB were analyzed in all 199 and showed different expression levels in fewer datasets than for CXCL10 , CXCL11 , and TNFSF10 . GADPH was found to be upregulated in 1 independent viral infection datasets, and downregulated in 6. TUBB was down in 3 viral infection datasets. ACTB was upregulated in 5 and downregulated in 9.

Article Snippet: A recombinant anti-human CXCL10 mouse IgG-monoclonal (MAB2661), anti-mouse IgG goat-polyclonal (AF-266-NA), and recombinant CXCL0 protein (Product 266-IP) were selected from R&D Systems (Toronto, Ontario, Canada).

Techniques: Microarray, In Vitro, Expressing, Infection

Journal: medRxiv

Article Title: Characterization of CXCL10 as a biomarker of respiratory tract infections detectable by open-source lateral flow immunoassay

doi: 10.1101/2024.01.12.24301261

Figure Lengend Snippet: A: Schematic of workflow. B: From Yu et al ., 2019 - GSE117827: CXCL10 , CXCL11 and TNFSF10 gene expression was compared from the mid-turbinate nasal swab of pediatric subjects with RSV, RV and negative controls. Clustered heatmap of log 2 expression levels annotated by symptomatic, sex and infection with blue representing decreased expression and red increased expression. On the right, boxplot of RMA normalized expression (log 2 ) (n = 24). There was no significant difference when comparing rhinovirus infected NPS to healthy control gene expression for CXCL10 , CXCL11 and TNFSF10 (p > 0.05). CXCL10 and CXCL11 up-regulation was positively correlated with Respiratory Syncytial Virus (RSV) when compared to healthy control (p = 0.016, p = 0.006). C: Hamilton Regional Laboratory Medicine Program (HRLMP) microarray data: CXCL10 , CXCL11 and TNFSF10 gene expression was compared from the NPS of subjects with influenza A (FluA) and negative controls. Clustered heatmap of log 2 expression levels annotated by sex and infection status with blue representing decreased expression and red increased expression. On the right, boxplot of RMA normalized expression (log 2 ) (n = 22). No significant difference between CXCL10 , CXCL11 and TNFSF10 expression in FluA infection compared to negative control (p > 0.05). D: From Lieberman et al ., 2020 - GSE152075: CXCL10 , CXCL11 and TNFSF10 gene expression was compared from the NPS of individuals with suspected SARS-CoV-2 infection. Clustered heatmap of log 2 expression levels annotated by sex and infection status with blue representing decreased expression and red increased expression. On the right, boxplot of RMA normalized expression (log 2 ) (n = 484). CXCL10 , CXCL11 and TNFSF10 expression was significantly upregulated SARS-Cov-2 infection compared to those who tested negative (p < 0.001). E: From Mick et al ., 2020 - GSE156063: CXCL10 , CXCL11 and TNFSF10 gene expression was compared from the NPS of subjects SARS-CoV-2 positive, SARS-CoV-2 negative but positive for another respiratory virus and no respiratory virus detected by metagenomic next generation sequencing (i.e., non-viral ARI such as bacterial infection). Clustered heatmap of log 2 expression levels annotated by sex and infection status with blue representing decreased expression and red increased expression. On the right, boxplot of RMA normalized expression (log 2 ) (n = 234). CXCL10 , CXCL11 and TNFSF10 expression was significantly upregulated SARS-Cov-2 infection compared to healthy control (p < 0.001). * = p < 0.05, ** p < 0.01 and *** = p < 0.001.

Article Snippet: A recombinant anti-human CXCL10 mouse IgG-monoclonal (MAB2661), anti-mouse IgG goat-polyclonal (AF-266-NA), and recombinant CXCL0 protein (Product 266-IP) were selected from R&D Systems (Toronto, Ontario, Canada).

Techniques: Gene Expression, Expressing, Infection, Control, Virus, Microarray, Negative Control, Next-Generation Sequencing

Journal: medRxiv

Article Title: Characterization of CXCL10 as a biomarker of respiratory tract infections detectable by open-source lateral flow immunoassay

doi: 10.1101/2024.01.12.24301261

Figure Lengend Snippet: A: Schematic of workflow. B : SARS-CoV-2 viral sequencing reads and qPCR cycle thresholds correlate with the CXCL10/CXCL11/TNFSF10 gene signature. (N = 735). The “Viral Level Continuous” comparison group converted qRT-PCR cycle threshold (Ct) values into a continuous variable by inverting CT values where Ct = 15 is equal to 1.0 and a Ct > 40 is 0, CXCL10 showed an upregulation of log 2 fold change of 6.2 (q value = 1.23E-54), CXCL11 showed an upregulation of log 2 fold change of 6.0 (q value = 5.17 E-47) and TNFSF10 showed an upregulation of log 2 fold change of 1.9 (q value = 4.26E-38). Data and Figure from Butler et al . 2021 - For research purposes only. All rights reserved. © Mason Lab and Weill Cornell Medicine, 2020). C: Mortality of COVID-19 patients is associated with only modest changes in the CXCL10/CXCL11/TNFSF10 gene signature at the time of original patient sampling. No significant correlation was found (p > 0.05).

Article Snippet: A recombinant anti-human CXCL10 mouse IgG-monoclonal (MAB2661), anti-mouse IgG goat-polyclonal (AF-266-NA), and recombinant CXCL0 protein (Product 266-IP) were selected from R&D Systems (Toronto, Ontario, Canada).

Techniques: Sequencing, Comparison, Quantitative RT-PCR, Sampling

Journal: medRxiv

Article Title: Characterization of CXCL10 as a biomarker of respiratory tract infections detectable by open-source lateral flow immunoassay

doi: 10.1101/2024.01.12.24301261

Figure Lengend Snippet: A: Schematic of workflow. B: CXCL10 , CXCL11 , and TNFSF10 expression over time in hospitalized COVID-19 positive patients expressed as % change from first sampling (set as time=0). The data was collected from 6 independent patients (COVXXX) who had distinct sampling counts dependent on clinical management of COVID-19 infection. COV005 = 5 measurements, COV006 = 3 measurements, COV007 = 5 measurements, COV010 = 6 measurements, COV011 = 10 measurements, COV013 = 11 measurements. C: To determine which gene fluctuated the least of the course sampling, the variance of RMA values for CXCL10/CXCL11/TNFSF10 were calculated for each patient (colours) and averaged (grey). CXCL11 variance = 0.17, CXCL10 variance = 0.21 and TNFSF10 variance = 1.68. * p < 0.05 relative to mean variance for CXCL10 and CXCL11 .

Article Snippet: A recombinant anti-human CXCL10 mouse IgG-monoclonal (MAB2661), anti-mouse IgG goat-polyclonal (AF-266-NA), and recombinant CXCL0 protein (Product 266-IP) were selected from R&D Systems (Toronto, Ontario, Canada).

Techniques: Expressing, Sampling, Infection

Journal: medRxiv

Article Title: Characterization of CXCL10 as a biomarker of respiratory tract infections detectable by open-source lateral flow immunoassay

doi: 10.1101/2024.01.12.24301261

Figure Lengend Snippet: A: Schematic of workflow. B-C: From Grassl et al ., 2016 ultra deep analysis of the healthy saliva proteome, the CXCL10 protein was not found amongst the list of 5562 identified proteins (Supplementary Table 2). D: CXCL10 Levels in saliva of SARS-CoV-2 in hospitalized COVID-19 patients quantified using the Human Cytokine Array / Chemokine Array 71-plex (Eve Technologies, Calgary, Alberta, Canada). Healthy volunteers without symptoms of a respiratory infection were used as the control group. Mean concentration of CXCL10 in saliva was 86.4 pg/mL (SD = 109.6, n = 6) in healthy subjects, while a mean of 1186.6 pg/mL (SD = 1252.3) was observed in COVID-19 patients. The COVID-19 group showed a significantly greater CXCL10 concentration (* = p < 0.05).

Article Snippet: A recombinant anti-human CXCL10 mouse IgG-monoclonal (MAB2661), anti-mouse IgG goat-polyclonal (AF-266-NA), and recombinant CXCL0 protein (Product 266-IP) were selected from R&D Systems (Toronto, Ontario, Canada).

Techniques: Infection, Control, Concentration Assay

Journal: medRxiv

Article Title: Characterization of CXCL10 as a biomarker of respiratory tract infections detectable by open-source lateral flow immunoassay

doi: 10.1101/2024.01.12.24301261

Figure Lengend Snippet: A: Schematic of workflow. B-C: Sensitivity development and validation in ideal buffer (10mM HEPES, 150 mM NaCl, 0.1% Tween-20, 1% BSA, and 0.5% PEG 8000 – see methods for more details). Limit of detection of CXCL10 using a hand-held reader. A positive signal is generated at 2ng/mL with n = 5. D-E: Sensitivity test in artificial saliva (product #1700-0316, ASTM E2721-16 with Mucin, pH 7.0; Pickering Laboratories, Mountain View, California, USA) prepared with equal parts lateral flow buffer and artificial saliva - see methods for more details. F: Real world testing in human saliva from healthy control without (neat) and with (spiked) CXCL10 (10ng/mL) addition.

Article Snippet: A recombinant anti-human CXCL10 mouse IgG-monoclonal (MAB2661), anti-mouse IgG goat-polyclonal (AF-266-NA), and recombinant CXCL0 protein (Product 266-IP) were selected from R&D Systems (Toronto, Ontario, Canada).

Techniques: Biomarker Discovery, Generated, Control